COMMUNIQUÉ DE PRESSE

par SARTORIUS STED BIO (EPA:DIM)

Sartorius Stedim Biotech: Information on Document Availability

Sartorius Stedim Biotech SA
Sartorius Stedim Biotech: Information on Document Availability

16-Feb-2024 / 09:23 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Aubagne, February 16, 2024

 

 

Sartorius Stedim Biotech: Information on Document Availability

 

 

Sartorius Stedim Biotech Group’s Universal Registration Document 2023 is now available at:

 

https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations/news-financial-publications

 

It contains the following information:

- Business development for fiscal 2023 and the 2024 forecast for the Sartorius Stedim Biotech Group

- Consolidated financial statements for the year ended December 31, 2023

 

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2023, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 10,600 employees are working for customers around the globe.


Contact
Petra Kirchhoff; Head of Corporate Communications and Investor Relations

Phone: +49(0)551.308.1686; petra.kirchhoff@sartorius.com

 

Follow Sartorius Stedim Biotech on Twitter @Sartorius_Group and on LinkedIn.

 

 

 


Regulatory filing PDF file

File: Sartorius Stedim Biotech: Information on Document Availability


Language:English
Company:Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:+33 44 284 5600
E-mail:sartorius.presse@sartorius.com
Internet:www.sartorius-stedim.com
ISIN:FR0013154002
Euronext Ticker:DIM
AMF Category:Additional regulated information to be pubicly disclosed under the legislation of a Member State / Terms of availability of a registration document or its updates
EQS News ID:1838837
 
End of AnnouncementEQS News Service

1838837  16-Feb-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1838837&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6
Voir toutes les actualités de SARTORIUS STED BIO